Dyslipidemia in Children Treated with a BRAF Inhibitor for Low-Grade Gliomas: A New Side Effect?
Marco CroccoAntonio VerricoClaudia MilanaccioGianluca PiccoloPatrizia De MarcoGabriele GaggeroValentina IurilliSonia Di ProfioFederica MalerbaMarta PanciroliPaolo GiordanoMaria Grazia CalevoEmilio CasaliniNatascia Di IorgiMaria Luisa GarrèPublished in: Cancers (2022)
BRAF inhibitors, in recent years, have played a central role in the disease control of unresectable BRAF-mutated pediatric low-grade gliomas (LGGs). The aim of the study was to investigate the acute and long-term effects of vemurafenib on the lipid metabolism in children treated for an LGG. In our cohort, children treated with vemurafenib ( n = 6) exhibited alterations in lipid metabolism a few weeks after starting, as was demonstrated after 1 month ( n = 4) by the high plasma levels of the total cholesterol (TC = 221.5 ± 42.1 mg/dL), triglycerides (TG = 107.8 ± 44.4 mg/dL), and low-density lipoprotein (LDL = 139.5 ± 51.5 mg/dL). Despite dietary recommendations, the dyslipidemia persisted over time. The mean lipid levels of the TC (222.3 ± 34.7 mg/dL), TG (134.8 ± 83.6 mg/dL), and LDL (139.8 ± 46.9 mg/dL) were confirmed abnormal at the last follow-up (45 ± 27 months, n = 6). Vemurafenib could be associated with an increased risk of dyslipidemia. An accurate screening strategy in new clinical trials, and a multidisciplinary team, are required for the optimal management of unexpected adverse events, including dyslipidemia.
Keyphrases
- low grade
- high grade
- low density lipoprotein
- clinical trial
- young adults
- wild type
- metastatic colorectal cancer
- respiratory failure
- squamous cell carcinoma
- high resolution
- intensive care unit
- hepatitis b virus
- extracorporeal membrane oxygenation
- drug induced
- mass spectrometry
- clinical practice
- gestational age
- phase iii